Cargando…

Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole

OBJECTIVE: Breast cancer is the most common cancer in women worldwide and the incidence increases in postmenopausal women. Anastrozole is a non-steroidal (type II), third-generation aromatase inhibitor (AI) that is used in the treatment of postmenopausal estrogen-related breast cancer. Several studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tugce Yesil, Devecioglu, Aydogan, Fatih, Omurtag, Gulden Zehra, Bese, Nuran Senel, Sardas, Semra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864710/
https://www.ncbi.nlm.nih.gov/pubmed/29607425
http://dx.doi.org/10.14744/nci.2017.55822
_version_ 1783308537070354432
author Tugce Yesil, Devecioglu
Aydogan, Fatih
Omurtag, Gulden Zehra
Bese, Nuran Senel
Sardas, Semra
author_facet Tugce Yesil, Devecioglu
Aydogan, Fatih
Omurtag, Gulden Zehra
Bese, Nuran Senel
Sardas, Semra
author_sort Tugce Yesil, Devecioglu
collection PubMed
description OBJECTIVE: Breast cancer is the most common cancer in women worldwide and the incidence increases in postmenopausal women. Anastrozole is a non-steroidal (type II), third-generation aromatase inhibitor (AI) that is used in the treatment of postmenopausal estrogen-related breast cancer. Several studies have been conducted to assess the efficacy, safety, and superiority of AIs to tamoxifen; however, a literature search did not reveal a study that investigated the genotoxic potential of AIs. The aim of this study was to investigate the possible DNA damage risk profile and individual DNA repair capacity of patients using anastrozole with the modified alkaline comet assay in order to contribute to public health and health economics. METHODS: Women diagnosed with breast cancer after menopause comprised the study group. Six patients who had taken anastrozole for at least 6 months were retrospectively enrolled, and 12 patients who had not yet received treatment were prospectively enrolled as a control group. Peripheral blood lymphocytes were used to measure oxidized DNA damage using formamidopyrimidine DNA-glycosylase (FPG) and endonuclease III (endo III) in a modified comet assay. Individual DNA repair capacity was evaluated with the comet assay after a hydrogen peroxide (H(2)O(2)) challenge to examine the difference in DNA damage susceptibility. RESULTS: Analysis of DNA damage, oxidative base damage, susceptibility to DNA damage, and repair capacity revealed no significant difference between the control group and the patients taking anastrozole (p>0.05). Susceptibility to H(2)O(2) damage was observed to increase with age (p<0.05). CONCLUSION: According to the results obtained in this study, anastrozole did not contribute to oxidative DNA damage. An H(2)O(2) challenge with the comet assay is useful to evaluate circumstances of increased vulnerability to damage, such as aging and cancer.
format Online
Article
Text
id pubmed-5864710
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Kare Publishing
record_format MEDLINE/PubMed
spelling pubmed-58647102018-03-30 Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole Tugce Yesil, Devecioglu Aydogan, Fatih Omurtag, Gulden Zehra Bese, Nuran Senel Sardas, Semra North Clin Istanb Original Article OBJECTIVE: Breast cancer is the most common cancer in women worldwide and the incidence increases in postmenopausal women. Anastrozole is a non-steroidal (type II), third-generation aromatase inhibitor (AI) that is used in the treatment of postmenopausal estrogen-related breast cancer. Several studies have been conducted to assess the efficacy, safety, and superiority of AIs to tamoxifen; however, a literature search did not reveal a study that investigated the genotoxic potential of AIs. The aim of this study was to investigate the possible DNA damage risk profile and individual DNA repair capacity of patients using anastrozole with the modified alkaline comet assay in order to contribute to public health and health economics. METHODS: Women diagnosed with breast cancer after menopause comprised the study group. Six patients who had taken anastrozole for at least 6 months were retrospectively enrolled, and 12 patients who had not yet received treatment were prospectively enrolled as a control group. Peripheral blood lymphocytes were used to measure oxidized DNA damage using formamidopyrimidine DNA-glycosylase (FPG) and endonuclease III (endo III) in a modified comet assay. Individual DNA repair capacity was evaluated with the comet assay after a hydrogen peroxide (H(2)O(2)) challenge to examine the difference in DNA damage susceptibility. RESULTS: Analysis of DNA damage, oxidative base damage, susceptibility to DNA damage, and repair capacity revealed no significant difference between the control group and the patients taking anastrozole (p>0.05). Susceptibility to H(2)O(2) damage was observed to increase with age (p<0.05). CONCLUSION: According to the results obtained in this study, anastrozole did not contribute to oxidative DNA damage. An H(2)O(2) challenge with the comet assay is useful to evaluate circumstances of increased vulnerability to damage, such as aging and cancer. Kare Publishing 2018-01-22 /pmc/articles/PMC5864710/ /pubmed/29607425 http://dx.doi.org/10.14744/nci.2017.55822 Text en Copyright: © 2018 by Istanbul Northern Anatolian Association of Public Hospitals http://creativecommons.org/licenses/by-nc-sa/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Original Article
Tugce Yesil, Devecioglu
Aydogan, Fatih
Omurtag, Gulden Zehra
Bese, Nuran Senel
Sardas, Semra
Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole
title Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole
title_full Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole
title_fullStr Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole
title_full_unstemmed Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole
title_short Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole
title_sort investigation of genotoxicity risk and dna repair capacity in breast cancer patients using anastrozole
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864710/
https://www.ncbi.nlm.nih.gov/pubmed/29607425
http://dx.doi.org/10.14744/nci.2017.55822
work_keys_str_mv AT tugceyesildevecioglu investigationofgenotoxicityriskanddnarepaircapacityinbreastcancerpatientsusinganastrozole
AT aydoganfatih investigationofgenotoxicityriskanddnarepaircapacityinbreastcancerpatientsusinganastrozole
AT omurtagguldenzehra investigationofgenotoxicityriskanddnarepaircapacityinbreastcancerpatientsusinganastrozole
AT besenuransenel investigationofgenotoxicityriskanddnarepaircapacityinbreastcancerpatientsusinganastrozole
AT sardassemra investigationofgenotoxicityriskanddnarepaircapacityinbreastcancerpatientsusinganastrozole